Table 2.
Diagnosis | Immunomodulatory treatment | ||
---|---|---|---|
Yes n (%) | Medication(s), number of patients | No n (%) | |
Control (n = 36) | 4 (11) | Betamethasone, n = 1; methotrexate, n = 1; methotrexate, prednisolone, and sulfasalazine, n =1; prednisolone, n = 1 | 32 (89) |
Diarrhea control (n = 22) | 0 (0) | N/A | 22 (100) |
Active LC (n = 9) | 0 (0) | N/A | 9 (100) |
LC-HR (n = 6) | 1 (17) | Budesonide, n = 1 | 5 (83) |
Active CC (n = 16) | 4 (25) | Budesonide, n = 3; cyclosporine and prednisolone, n = 1 | 12 (75) |
CC-HR (n = 6) | 2 (33) | Budesonide, n = 1; budesonide and sulfasalazine, n = 1 | 4 (67) |
Active UC (n = 15) | 10 (67) | Mesalazine, n = 8; mesalazine and methotrexate, n = 1; olsalazine, n = 1 | 5 (33) |
UC remission (n = 12) | 6 (50) | Balsalazide, n = 1; mesalazine, n = 1; olsalazine, n = 1; sulfasalazine, n = 3 | 6 (50) |
LC, lymphocytic colitis; LC-HR, lymphocytic colitis in histological remission; CC, collagenous colitis; CC-HR, collagenous colitis in histological remission; UC, ulcerative colitis.